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One approach to improve contraction in the failing heart is the administration of calcium (Ca2+) sensitizers.
Although it is known that levosimendan and other sensitizers bind to troponin C (cTnC), their in vivomechanism
is not fully understood. Based on levosimendan, we designed a covalent Ca2+ sensitizer (i9) that targets C84 of
cTnC and exchanged this complex into cardiac muscle. The NMR structure of the covalent complex showed
that i9 binds deep in the hydrophobic pocket of cTnC. Despite slightly reducing troponin I afﬁnity, i9 enhanced
the Ca2+ sensitivity of cardiac muscle. We conclude that i9 enhances Ca2+ sensitivity by stabilizing the open
conformation of cTnC. These ﬁndings provide new insights into the in vivo mechanism of Ca2+ sensitization
and demonstrate that directly targeting cTnC has signiﬁcant potential in cardiovascular therapy.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Decreased cardiac contractility is a characteristic of a variety of heart
diseases including systolic heart failure. One approach to treating this
condition is to administer positive inotropes that increase cardiac mus-
cle contraction by increasing intracellular Ca2+ concentration. Although
beneﬁcial in the short-term, over time this can lead to the development
of arrhythmias and myocyte death due to Ca2+ overload [1]. An
emerging alternative is the administration of Ca2+ sensitizers, a class
of inotropes that act directly on the contractile proteins of the heart
[1]. The best clinically characterized Ca2+ sensitizer is levosimendan;
however, its mechanism of action in vivo is still not fully understood.
This work provides insight into the molecular mechanism behind
Ca2+ sensitization by characterizing the in vitro structure and ex vivo
function of cTnC with a covalently bound levosimendan analog.
Contraction is regulated in the heart muscle by troponin (cTn) in a
Ca2+ dependent manner. cTn is a complex composed of C, I, and T
subunits (cTnC, cTnI, and cTnT, respectively) localized to the thin
ﬁlament of the sarcomere. cTnC contains two globular domains: the
regulatory N-domain (cNTnC) that acts as the Ca2+ sensor, and the
structural C-domain that anchors cTnC on the thin ﬁlament. During
systole, when the cytosolic Ca2+ concentration increases, Ca2+ binds
to cNTnC and increases the prevalence of the open conformation of
cNTnC [2,3]. Following this conformational change, the switch region
of cTnI (switch-cTnI) binds to cNTnC and drags the inhibitory and
C-terminal regions of cTnI away from actin. This leads to an allosteric
change in tropomyosin exposing the myosin binding sites on actin to
promote the formation of the force-producing cross-bridges [4,5].
One of the most widely studied Ca2+ sensitizers is levosimendan.
While levosimendan binds to cTnC in vitro, the details of its in vivo
action are not clear. Besides Ca2+ sensitization, levosimendan has
also been shown to have vasodilatory, anti-inﬂammatory, and anti-
apoptotic effects [6,7]. Although levosimendan inhibits phosphodiester-
ase 3 (PDE3) at high concentrations, its positive inotropic effect is
thought to be due to its interaction with cTnC and not to an increase
in intracellular Ca2+ [8–11]. Previous NMR studies showed that in
the presence of cTnI, levosimendan interacts only with the regulatory
N-domain [12]. No three-dimensional structure has been determined
due to the short lifetime of the cTnC·levosimendan complex. Using
amide chemical shift mapping by NMR, Sorsa and coworkers found
widespread chemical shift perturbations throughout the N-domain
but could not determine a speciﬁc binding site [13]. Methioninemethyl
chemical shift perturbations, however, suggest levosimendan binds in
the hydrophobic cleft of cNTnC [14].
Other studies have shown that C84 is essential for binding [14,15]. In
a study published by Kleerekoper and Putkey, levosimendan did not
bind to the N-domain of cTnC when C84 was mutated to a serine [16].
The authors also reported no binding in the presence of C84; however
it has been since shown that the sulfhydryl-containing reducing agent
used in that study, dithiothreitol (DTT), reacts with levosimendan and
prevents its binding to cNTnC [13,14]. Levosimendan contains two
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nitrile groups that can undergo nucleophilic addition in the presence
of thiol groups. We have hypothesized that levosimendan can form a
reversible covalent bond with C84 of cNTnC (Ian M. Robertson et al.
2016, in preparation).
There have been a number of studies that indicate that small
molecules that bind to cTnC also alter Ca2+ sensitivity [17,18], but it is
not clear if this interaction is directly responsible for the increased
contractility in the muscle. For example, EMD57033 was shown to
bind to cTnC and increase Ca2+ sensitivity and the force of contraction.
However, after the structure of EMD57033 bound to cTnC was solved
[19], it was shown that EMD57033 likely enhances contractility by
stabilizing actomyosin cross-bridges rather than through its interaction
with cTnC [20]. The lack of direct evidence for levosimendan binding to
cTnC in cardiac muscle has also fueled the debate over whether
levosimendan functions primarily as a Ca2+-sensitizer [21], a PDE3
inhibitor [22] or by some combination of the two mechanisms [11].
The K+-channel activation and subsequent vasodilation effect of
levosimendan [23] has further complicated characterization of its
in vivo function [24].
To investigatewhether a smallmolecule thatwe are certain is bound
to cTnC can increase Ca2+ sensitivity in cardiac muscle, we designed a
novel levosimendan analog (i9) that covalently reacts with cTnC
(Fig. 1) and replaced native cTnC with this complex in cardiac trabecu-
lae. We studied the effect of i9 attached to cTnC(C35S) on contractility
ex vivo and on switch-cTnI binding to cNTnC in vitro. We determined
the NMR structure of a stable cNTnC·switch-cTnI hybrid protein
(cChimera) with i9 covalently bound to C84. The results demonstrate
that i9 increases the Ca2+ sensitivity of contraction in cardiac muscle
despite having a slightly reduced afﬁnity of switch-cTnI for cTnC(C35S).
This occurs because TnI is tethered to TnC in the muscle cell. Our
structure shows that i9 binds in the hydrophobic cleft of cNTnC in
close proximity to switch-cTnI. We conclude that i9 enhances muscle
Ca2+ sensitivity by stabilizing an open conformation of cNTnC. These
ﬁndings provide new insights into the in vivo mechanism of Ca2+
sensitization and demonstrate that directly targeting cTnC has signiﬁ-
cant potential as a cardiovascular therapy.
1. Results and discussion
1.1. Design of i9
To investigate the mechanism of action of levosimendan, we
designed i9 based on the structures of levosimendan and its analog
dfbp-o (Fig. 1). The three molecules contain a biphenyl group followed
by a hetero-substituted moiety. The biphenyl group of dfbp-o was cho-
sen because it was shown to insert in the hydrophobic cleft of cNTnC,
conserve the Ca2+ sensitization effect [25], and be advantageous for
ﬂuorine NMR [26]. The hetero-substituted moiety of i9 was designed
based on the proposed reactivity of the nitrile group of levosimendan.
A reactive iodoacetamide groupwas incorporated such that the number
of bonds separating the biphenylmoiety and the sulfur atom of C84was
the same as with levosimendan (Fig. 1). The covalent analog i9 has a
planar center on the amide N, which closely resembles levosimendan.
1.2. Synthesis and puriﬁcation of i9
To synthesize the covalent levosimendan analog i9, we followed the
route outlined in Supporting Figure 1. Supporting Figure 1b shows the
1HNMR spectra of 1, 2, and i9 in DMSO-d6.With the addition of the ace-
tyl chloride moiety the signal corresponding to N8 is shifted downﬁeld
(from 8.36 to 8.75 ppm) as the result of deshielding by the newly at-
tached carbonyl C9, also a new aliphatic signal at 4.35 ppm is observed
corresponding to the new methylene protons at C10. The halogen
exchange from Cl to I shifted the H10 singlet upﬁeld (from 4.12 to
3.71 ppm) due to the less electronegative character of I compared to
Cl. Both reactions had only small effects on the aromatic protons of
the products, which were assigned with aid from previous assignment
of dfbp-o [25].
Fig. 1.The covalent levosimendan-analog i9. Structures of i9, levosimendan, and dfbp-o. Arrows point to reactive carbon atoms. The structures of i9 and levosimendan reactedwith C84 are
shown. Carbons 4 and 11 are labeled to delimitate the spacer region between the biphenyl moiety and Sγ of C84. Atoms with trigonal planar geometry are marked with *.
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1.3. Troponin labeling with i9
Three proteins were independently reacted with i9: cTnC(C35S)
for physiological characterization, cNTnC for assessment of reaction
speciﬁcity, and 13C,15N-cChimera for structure determination by NMR.
cChimera is a hybrid protein which contains cNTnC (residues 1–89) and
switch-cTnI (residues 144–173) that represents the cNTnC·switch-cTnI
complex prevalent during the systolic state of the heart [27]. The labeling
reactionswere performed in urea or NMR buffer, and veriﬁed by 19F NMR
and mass spectrometry.
Protein labeling is illustrated for cChimera in Fig. 2a, where the 19F
NMR spectrum of i9 (spectrum 1) shows two sharp signals at −36.2
and−39.3 ppm corresponding to the ﬂuorine atoms F4′ and F2′. After
the reaction with cChimera (spectrum 2) the two ﬂuorine signals shift
(to −36.4 and −37.1 ppm) and broaden as a result of a change in
environment andmolecular size, respectively. To assess the completion
of the reaction, 0.2 mM-bromo-1,1,1-triﬂuoroacetone was added to
cChimera-i9 to react with any remaining free sulfhydryl group present
(spectrum 3). The presence of the unreacted triﬂuoroacetone only, as
a sharp singlet at−8 ppm, indicates that the reaction with i9 was com-
plete. Spectrum 4 shows the chemical shift of triﬂuoroacetone bound to
cChimera in a different sample for reference.
Fig. 2b displays a summary of the 19F spectra of all the reacted pro-
teins. Full labeling of cNTnCwith excess i9 in urea results in covalent bind-
ing at C35 and C84, but only the signals corresponding to C84-i9 sharpen
in the presence of cTnI. The 19F spectrum of cNTnC-i9 in the absence
of switch-cTnI (Fig. 2b, spectrum 1) shows two sharper signals corre-
sponding to F2′ and F4′ of C35-i9, and broader signals for C84-i9, which
indicates multiple conformations for C84-i9. Addition of a 3:1 excess
switch-cTnI (residues 144–173), which binds to cNTnC, causes the ﬂuo-
rine signals of C84-i9 to sharpen. This indicates that binding of switch-
cTnI to cNTnC stabilizes C84-i9 in one conformation. In a similar way,
the 19F spectrum of cTnC(C35S)-i9 (spectrum 2) shows the same change
in linewidth for F2′ and F4′ of C84-i9 upon addition of switch-cTnI. For
cChimera-i9 (spectrum 4), in which switch-cTnI is bound to cNTnC, the
C84-i9 signals are very similar to those of cTnC(C35S)-i9 and cNTnC-i9
in the presence of switch-cTnI. Comparable spectra indicate similar elec-
tronic environments for i9 in all cases. Thus, the i9 molecule is expected
to adopt the same conformation in all cNTnC·switch-cTnI systems. This
validates the use of cChimera for structural characterization of their
interaction.
The reaction of i9 with cNTnC in aqueous NMR buffer using a small
drug-to-protein excess (1.1:1) resulted in preferential labeling on C84
as judged by the appearance of intense C84-i9 peaks and minuscule
C35-i9 peaks (spectrum 3). For an unspeciﬁc reaction, equal labeling
of C35 and C84 would be expected. Selective labeling of C84 with i9 is
most likely the result of a two-step process as is the case for covalent
inhibitors [28]. Initially, non-covalent binding to the target protein posi-
tions the reactive groups close in space. Then the complex undergoes
bond formation.
1.4. Ca2+ sensitizing effect of cTnC(C35S)-i9
We investigated the effect i9 had on contraction in demembranated
ventricular trabeculae containing cTnC(C35S)-i9. Following the
exchange of native cTnC for cTnC(C35S)-i9 in ventricular trabeculae,
an increase in the Ca2+-sensitivity of force development was observed
(Fig. 3). The data were ﬁtted with the Hill equation (Eq. (1)) and the
pCa50 increased from 6.10 ± 0.01 (SEM; n = 7) to 6.22 ± 0.01 (SEM;
n = 7) (P b 0.05). The maximum Ca2+-activated isometric force was
25.3 ± 1.7 mN mm−2 (SEM; n = 8) prior, and 24.6 ± 2.7 mM mm−2
(SEM; n=7) after exchange of cTnC. Thus, cTnC(C35S)-i9 did not affect
maximum Ca2+-activated force, which is consistent with the observa-
tions made for the Ca2+-sensitizers dfbp-o [25] or levosimendan [29].
We also observed a decrease in the Hill coefﬁcient (an indicator of
cooperativity) from 4.62 ± 0.53 (SEM; n = 7) to 2.90 ± 0.34 (SEM;
n = 7) following exchange. A similar decrease in cooperativity has
been observed for other Ca2+ sensitizers [30] as well as several Ca2+-
sensitizing mutations [31]. The amount of cTnC(C35S)-i9 exchanged
within the muscle was estimated to be 20% by LC-MS. When a higher
fraction of native cTnC in trabeculae was replaced by cTnC(C35S)-i9,
Fig. 2. Troponin labeling with i9. a, stack of 19F spectra of i9 (1), cChimera-i9 (2), and cChimera-i9 in the presence of 3-bromo-1,1,1-triﬂuoroacetone (3) showing complete reaction of
cChimera with i9. Spectrum 4 shows triﬂuoroacetone bound to cChimera for reference. b, stack of 19F spectra of cNTnC-i9, cTnC(C35S)-i9, and cChimera-i9 in the absence and presence
of switch-cTnI. The reaction column speciﬁes labeling conditions.
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active force developed in relaxing (pCa 9) conditions. This suggests that
i9 stabilizes a conformation of cTnC similar to that stabilized by Ca2+.
Because i9 is covalently attached to C84, the observed increase in
Ca2+ sensitivity can be unequivocally attributed to i9 binding to
cNTnC. This is in contrast to traditional experiments in which muscle
is soaked in solutions containing a drug under study [32–36] leaving
the in situ target uncertain. Since cTnC shares many structural features
with other contractile EF-hand regulatory proteins, such as the myosin
regulatory and essential light chains [37], it is always a concernwhether
changes in contractility are due exclusively to binding to cTnC.
1.5. Conformation of cNTnC(C35S)-i9
To investigate if i9 stabilizes the open conformation of cNTnC in the
absence of switch-cTnI, we compared the 15N and 1H amide chemical
shifts of cNTnC(C35S)-i9 with those of cNTnC in the absence and pres-
ence of switch-cTnI, which are characteristic of the closed and open
states [38], respectively (Fig. 4). In most cases, resonances of cNTnC-i9
lie between those of cNTnC and cNTnC·switch-cTnI, suggesting
cNTnC-i9 adopts a partly open conformation. Interestingly V72 is shifted
further than the resonance indicative of the open conformation.
Residues such as V72, D73, and E32 display more than one signal for
their amide NH resonances indicative of multiple conformations.
These results support our earlier supposition that i9 is in more than
one conformation in the absence of switch-cTnI (Fig. 2b, spectra 1–3).
To quantify the predicted conformation of cNTnC-i9, we used
ORBplus [38]. ORBplus uses amide chemical shifts to predict the AB
and CD interhelical angles, which are good indicators of the overall
conformation of cNTnC (angles closer to 90° indicate a more open
conformation). Residues in or near Ca2+ binding site I (27–40) are
good indicators of the AB interhelical angle, and residues in or near
site II (64–74) are good indicators of the CD interhelical angle [38].
Due to the presence of multiple peaks and exchange broadening for
some cNTnC-i9 residues, it was not possible to obtain complete assign-
ment of all residues in sites I and II. Using the amide chemical shifts of
L29, G30, A31, E32, G34, and S35, the AB interhelical angle is predicted
to be 133°, which is 9° more open than cNTnC (142°). Using resides
E66, D67, G68, V72, D73 and F74, the CD interhelical angle is 105°,
which is 4° more open than cNTnC (109°) (Table 1). These results indi-
cate than i9 partially opens cNTnC and suggest that the AB-interhelical
angle is more sensitive to i9 binding than is the CD interhelical angle.
A similar magnitude of change (ΔAB = 10°; ΔCD = 5°) was observed
for the Ca2+-sensitizingmutation, L48Q [38], which suggests that alter-
ing theAB interhelical angle, even just slightly, can signiﬁcantly increase
Ca2+-sensitivity.
1.6. Effect of i9 on switch-cTnI binding to cTnC(C35S)
Along with the stabilization of the open state of cNTnC, enhanced
switch-cTnI binding has been proposed to increase Ca2+ sensitivity
[25]. To evaluate the effect of i9 on switch-cTnI binding, we titrated
Ca2+-saturated cTnC(C35S)-i9 with switch-cTnI (residues 144–163)
and monitored it by 19F NMR spectroscopy. The change of area under
the F4′ signal of i9 as a function of increasing switch-cTnI concentration
was ﬁt to a binding curve with 1:1 stoichiometry and a dissociation
constant (KD) of 74± 26 μM (SD, Fig. 5). This corresponds to an afﬁnity
approximately three times lower than that for the binding of switch-
cTnI (residues 144–163) to cNTnC in the absence of i9 (KD = 26 ±
4 μM (SD)) [25]. Likewise, the Ca2+-sensitizer, bepridil, was also
shown to reduce the afﬁnity of switch-cTnI [39]. Thus, our results
indicate the Ca2+ sensitizing effect of i9, like bepridil, does not involve
enhancing switch-cTnI binding. Interestingly, bepridil also impairs
Fig. 3. Effect of i9 on muscle ﬁber contraction. Force-pCa relationship of ventricular
trabeculae containing wild type cTnC (WT) and cTnC(C35S)-i9 (i9). Data points are
means ± SEM (n= 7).
Fig. 4. Conformation of cNTnC(C35S)-i9. Overlap of regions of the 1H,15N-HSQC NMR spectra of cNTnC (black) representative of the closed state, cNTnC·switch-cTnI (blue) representative
of the open state, and cNTnC-i9 displaying an intermediate state (pink).
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the cooperativity of contraction [30], and thus the reduced afﬁnity of
switch-cTnI may help explain the reduced cooperativity observed in
the Ca2+-sensitivity experiments [31].
Bepridil has been shown to enhance Ca2+ afﬁnity of cTnC [40,41]
and of various troponin complexes [42] through stabilizing the open
conformation of cNTnC [43] and slowing the rate of Ca2+ dissociation
[40,44]. Despite enhancing Ca2+ afﬁnity, bepridil actually increases
the speed of transition from the open, cTnI-bound, conformation of
cNTnC to the closed, cTnI dissociated, conformation of cNTnC [42].
This observation is probably due to the reduced afﬁnity of switch-cTnI
for the cNTnC-bepridil complex [39,42], and seems to suggest that
paradoxically, despite enhancing Ca2+ afﬁnity, bepridil may also pro-
mote diastolic relaxation [42]. Therefore, given the similar reduction
in switch-cTnI afﬁnity for cNTnC-i9, one may expect a similar enhance-
ment of the relaxation rate of contraction as proposed for bepridil. It is
important to note, as mentioned above, that substitution of N20% of
native cTnC with cTnC(C35S)-i9 led to active force generation even in
the absence of Ca2+. Therefore, although covalently bound i9 may pro-
mote the rate of cTnI dissociation, its prevention of complete relaxation
limits its use as a treatment of heart failure.
On the other hand, levosimendan, which has also been shown to
increase Ca2+ afﬁnity [15,45], did not show the enhanced transition
rate from an open conformation to a closed conformation that was
observed for bepridil [42]. This suggests that levosimendandoes not com-
petewith switch-cTnI and that itsmechanism for Ca2+-sensitizationmay
bedifferent thanbepridil's (and therefore also i9).However, in that study,
C35 and C84 were mutated to serines in order to accommodate
ﬂuorophore labeling at other non-native cysteine residues [42]. Therefore
the lack of C84, which is critical for levosimendan binding [14,15],
coupled with the relatively minor impact of levosimendan on Ca2+-
sensitivity [42], makes interpretation of this ﬁnding and how it applies
to the mechanism of i9 unclear.
Finally, it is also possible that the 3-fold decrease in switch-cTnI
afﬁnity in the micromolar range (~25 to 75 μM) may not be signiﬁcant
in the context of the high apparent concentration of switch-cTnI in the
thin ﬁlament. cNTnC and switch-cTnI are spatially conﬁned in the thin
ﬁlament such that the apparent concentration of switch-cTnI is high.
We previously designed cChimera to mimic the in situ conditions
of the thin ﬁlament. In this hybrid protein, cNTnC and switch-cTnI
are tethered and the apparent concentration of switch-cTnI was
determined to be ~1 mM [27]. Based on paramagnetic relaxation
enhancement-NMR data, the Brown group also suggested that switch-
cTnI remains in the vicinity of cTnC in the absence of Ca2+ [46].
1.7. Structure of cChimera-i9
To characterize the interaction of a covalent Ca2+ sensitizerwith the
regulatory cNTnC·switch-cTnI complex,we determined the structure of
cChimera-i9. In cChimera, the high apparent concentration of switch-
cTnI keeps the complex in a switch-cTnI-saturated state [27]. This
design allows for structural assessment of cNTnC·switch-cTnI as it is
found during systole in the heart. The structure of cChimera-i9 (Fig. 6;
Supporting Figure 2) is similar to the structure of the cNTnC·switch-
cTnI complex observed in other structures (see Table 1 for a list of
interhelical angles). When cNTnC and switch-cTnI in cChimera-i9 are
compared to those in the x-ray structure of the core domain of cTn
[47], the rmsd of alpha carbons is 2.2 Å for all residues and 2.0 Å for
helical residues. Compared to those in the NMR structure of dfbp-o
bound to cNTnC·switch-cTnI, the rmsd of alpha carbons is 2.2 Å for all
residues and 2.1 Å for helical residues. The structure has been deposited
in the Protein Data Bank (PDB) and the Biological Magnetic Resonance
Table 1
Inter-helical angles of cNTnC structures.a The smaller the interhelical angle, themore open
the cNTnC structure is. The reference closed state of cNTnC used by ORBplus is highlighted
in grey.
cNTnC structures PDB code ABa,b CDa,c
cNTnC(C35S)-i9 (calculated with ORBplus)d – 133 105
cChimera-i9d 2N7L 99 ± 10° 91 ±  8° 
cNTnC(acys)-Ca2+ 2CTN 142 ± 3° 109 ± 4°
cNTnC-Ca2+-cTnI147–163 1MXL 102 ± 4° 95 ± 6°
cTnC(acys)-3Ca2+-cTnI31-210-cTnT183–288 1J1D 104° 96°
cTnC(acys)-3Ca2+-3bepridil 1DTL 93° 89°
cNTnC-Ca2+-cTnI147–163-bepridil 1LXF 121 ± 4° 85 ± 4°
cNTnC(acys)-Ca2+-W7 2KFX 114 ± 3° 86 ± 2°
cNTnC(acys)-Ca2+-cTnI147–163-W7 2KRD 112 ± 5° 63 ± 6°
cNTnC(acys)-Ca2+-cTnI144–163–dfbp-o 2L1R 96 ± 6° 89 ± 6°
aAngles calculated with the program Interhlx (K. Yap, University of Toronto).
bAB interhelical angleswere determined by deﬁning the C helix as residues 17–26, and the
D helix was deﬁned as residues 40–46 for all structures.
cCD interhelical angleswere determined by deﬁning the C helix as residues 54–62, and the
D helix was deﬁned as residues 75–83 for all structures.
dThis work.
Fig. 5. Effect of i9 on switch-cTnI binding to cTnC. Stack of 19F NMR spectra (top) and
binding curve (bottom) for the titration of switch-cTnI into cTnC(C35S)-i9.
178 S.E. Pineda-Sanabria et al. / Journal of Molecular and Cellular Cardiology 92 (2016) 174–184
Data Bank (BMRB) under the ID 2N7L and 25810, respectively. Structur-
al statistics for the ﬁnal ensemble are summarized in Supporting
Table 1.
The typical structural features of cNTnC in the Ca2+ and switch-TnI
bound state are present in the structure of cChimera-i9. It contains
ﬁve α-helices, N and A through D, and a small β-sheet involving the
loops of each EF-hand. Helices N and D in cChimera-i9 are extended
by 2 and 5 residues, respectively (D2-D3 and K86-E90). The linker re-
gion between cNTnC and switch-cTnI in cChimera remains ﬂexible.
We conﬁrmed the ﬂexibility of the linker using the random coil index
(RCI) analysis performed within TALOS+, which estimates values of
the model-free order parameter S2 based on the chemical shift of CA,
CB, N, HA, and NH, backbone atoms [48]. The RCI indicates that residues
95 and 96 of the linker alongwith 144–147 of cTnI have S2 b 0.5 and are
classiﬁed as dynamic.
1.8. Structure of cTnI in cChimera-i9
Switch-cTnI in cChimera-i9 forms an α-helix that is slightly shifted
away from the core of the protein. The length and composition of the
switch helix of TnI in cChimera-i9 is the same as that observed in the
crystal structure of the troponin core domain (1J1E) [47], starting at res-
idue A150 and continuing until residue L158 with the adjacent regions
being unstructured. The switch helices of both structures are roughly
parallel and localize between the A-B-D helices of cNTnC. One possible
explanation for the shift in switch-cTnI position relative to cNTnC is
a steric clash between i9 and A150, at the start of the switch-helix,
and/or M153, which faces the hydrophobic cleft of cNTnC (Fig. 7). De-
spite this steric clash between switch-cTnI and i9, cNTnC is in an open
conformation. The AB interhelical angle is 99° and the CD interhelical
angle is 91°, which are similar to the interhelical angles measured for
cNTnC bound to switch-cTnI (Table 1). Interestingly, this is in contrast
to W7 and bepridil, both of which also compete with switch-cTnI bind-
ing. This difference may be due to the fact that both i9 and switch-cTnI
are covalently bound to cNTnC in the cChimera structure.
1.9. Structure of i9 in cChimera-i9
Fourteen NOE distance restraints deﬁne the position of i9 in the core
of cChimera between helices B, C, and D of cNTnC, and the helical region
of switch-cTnI. The diﬂuorophenyl ring of i9 contacts residues I61 and
V64 on helix C, and I36 and V72, which form part of the β-sheet of
cNTnC (Fig. 8); this is consistent with its position deep in the hydropho-
bic cleft. The middle phenyl ring of i9 contacts several residues on the
middle region of the cleft such as L41, V44, and M45 on helix C and
M80 on helix D. This ring also makes NOEs to M85 on helix D and
V146 on switch-cTnI, which are located towards the protein surface
(Fig. 8).
The binding site of i9 is comparable to that of other drugs that inter-
act with cTnC such as bepridil, dfbp-o, andW7 [25,39,49]. Compared to
dfbp-o, i9 binds deeper in the pocket (Fig. 6). This indicates that the
length of the hetero-substituted moiety of i9 is adequate to allow for
deep binding (Fig. 1). Because this moiety of i9 was designed based on
that of levosimendan, we propose that levosimendan binds in a similar
fashion once it reactswithC84. The spacer between thebiphenylmoiety
of i9 and the reactive thiol of cNTnC (C4 of i9 to Sγ of C84, Fig. 1) has one
double and four single bonds, the same as levosimendan would have
once reacted with C84 (C11 of levosimendan to Sγ of C84, Fig. 1).
However, the planarity of levosimendan in the spacer is extended
compared to that of i9, which may slightly alter its conformation
when bound.
Fig. 6. Structure of cChimera-i9. The lowest energy structure of cChimera-i9 (pink) shows the his-tag and linker region in grey. Helices on cNTnC are labeled N and A through D, the switch
region of cTnI is labeled, i9 is in orange sticks, Ca2+ ions are shown as spheres. The linker region is not shown in the overlays for clarity. The structures of cNTnC·switch-cTnI (yellow) and
cNTnC·switch-cTnI·dfbp-o (blue) were aligned to cChimera-i9 using the alpha carbons of all helices. The expansion shows the positions of i9 and dfbp-o in the hydrophobic pocket of
cNTnC
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Although no high-resolution structure of levosimendan bound
to cTnC has been published, some studies have provided structural
information about its binding site [14,45]. In a complex between
levosimendan and Ca2+-saturated cNTnC (residues 1–91), NOEs
between levosimendan and M85, M81 and F77 from cNTnC were
tentatively assigned [45]. More recently, the 13C chemical shifts of
methionine methyl groups from Ca2+-saturated cTnC(C35S) were
monitored by 1H, 13C-HSQC NMR spectroscopy before and after
levosimendan binding [14]. The residues that experienced the largest
chemical shift perturbations following levosimendan binding were
M85, M81 and M47, suggesting that they are in close proximity to
levosimendan [14]. In the cChimera-i9 structure in our study, i9
makes NOE contacts with M85, M80, and M45, which suggest that i9
and levosimendan have a similar binding site. It is worthwhile to note
that the structural studies on levosimendan were done in the absence
of cTnI; thus, the slight differences between studies may be the result
Fig. 8. NOEs between i9 and cChimera. Planes from the three dimensional noesyChsqc_CNﬁlt NMR spectrum corresponding to each aromatic proton of i9 in cChimera-i9. The name and
chemical shift of the i9 protons are labeled in the upper left corner of each plane. The NOEs to protons on cChimera (lowest energy structure) are also labeled and depicted in the panels on
the right. In the panels, helices and residues of cNTnC (pink) are labeled, as well as the distances to i9 (orange) protons corresponding to the observed NOEs.
Fig. 7. Potential steric clash between i9 and cTnI. The alpha carbons of cNTnC from the structure of cChimera-i9 and from the x-ray structure of the core domain of cTn (yellow) are aligned.
Although both cNTnC and switch-cTnI from the x-ray structure are shown, only the i9molecule and C84 from the structure of cChimera-i9 are shown (orange sticks). Two representative
models from the ﬁnal ensemble of cChimera-i9 are depicted: on the left is the lowest energymodel and on the right is themodel closest to the averagemodel. Two residues from the x-ray
structure that clash with i9 in each model are A150 and M153 (yellow sticks).
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of the presence of cTnI. For example, residuesM81 andM47 lie at the in-
terface formed between cNTnC and cTnI; therefore it is plausible that in
the presence of cTnI, levosimendanwould adopt a similar conformation
as that seen for i9 in the cChimera complex.
We propose that i9 has a similar effect as Ca2+ to enhance contrac-
tion (Fig. 9). cNTnC is in equilibrium between open and closed confor-
mations. Ca2+ binding to cNTnC shifts the equilibrium to the open
state to allow the binding of switch-cTnI [2,3,50]. Our results indicate
that the Ca2+-sensitizer i9 is sufﬁcient to turn on contraction, regardless
of its effect on switch-cTnI binding. i9 may stabilize the open conforma-
tion either through shifting the equilibrium towards the open state or
through preventing complete closure of cNTnC, even following Ca2+
release. This can be extended to the mechanism of action of other
Ca2+ sensitizing agents that bind to cTnC. Details of the interaction of
the sensitizers bepridil, dfbp-o, levosimendan, i9, and the desensitizer
W7 with cNTnC are summarized in Table 2. All of these molecules
favor the open state of cNTnC, regardless of their effect on Ca2+ sensiti-
zation. This suggests that there is another downstream mechanism
responsible for their differential effect on contractility. One possible
explanation is that they alter the afﬁnity of switch-cTnI for cNTnC
(increased by Ca2+-sensitizers and decreased by desensitizers).
Although the effects of dfbp-o and W7 on switch-cTnI conform to this
hypothesis, bepridil and i9 do not; both compete with switch-cTnI yet
still enhance contraction. However, the decrease in switch-cTnI
afﬁnity is relatively minor when compared to W7 and is likely not
physiologically relevant.
In conclusion, we have shown that if we ensure that the drug under
study is bound to the designated target protein in the muscle, by cova-
lently linking it to that protein and then exchanging the complex into
the muscle, then it has the effect predicted on the basis of the in vitro
mechanism. We did discover that the in situ mechanism overcomes
one of the kinetic limitations of the in vitro mechanism from the co-
localization of the proteins involved in the ﬁnal conformational cascade
that triggers contraction.Weanticipate that this knowledge can lead the
design of novel Ca2+ sensitizers for cardiac muscle.
2. Methods
2.1. Puriﬁcation of troponin
cTnC(C35S), 13C-15N-cChimera, and 15N-cChimera were expressed
in E. coli as described elsewhere [51]. cChimera contains a histidine
tag, a thrombin cleavage site (GGLVPRGS), cNTnC (residues 1–89), a
TEV cleavage site (ENLYFQG), and switch-cTnI (residues 144–173).
We previously showed that cChimera resembles the cNTnC·switch-
cTnI complex in the ~74% bound state [27]. The cChimera proteins
were puriﬁed byNi-NTA afﬁnity followed by gel ﬁltration chromatogra-
phy as previously reported [27]. 15N-cNTnC(C35S) was obtained by TEV
cleavage of 15N-cChimera [27]. The DNA from cTnC(C35S, C84S) [52]
was used as a template for the preparation of cTnC(C35S) using a site-
directedmutagenesis kit and cTnC(C35S)was puriﬁed as previously de-
scribed [53]. The purity of the proteins was veriﬁed by reverse-phase
HPLC and electrospray ionization Mass Spectrometry (ESI-MS). The syn-
thetic cTnI peptide (residues 144–173) was obtained from GL Biochem
Ltd. (Shanghai, China).
2.2. Synthesis and puriﬁcation of i9
Chloroacetyl chloride was from Fluka Analytical (≥99% GC), (2′,4′-
diﬂuorobiphenyl-4-yl) methanamine (97%, compound 1) from Amatek
Chemical, and ethyldiisopropylamine (Hunig's Base, HB) was from
Sigma-Aldrich (99.5%). In a glass vial 50 μmol of 1 and 170 μmol of HB
were dissolved in 1.2 mL of acetonitrile. In a separate glass vial,
500 μmol of chloroacetyl chloridewere dissolved in 40 μL of acetonitrile
and slowly added into the 1/HB solution under the extraction hood. The
reaction produced gas (HCl) and turned to pale yellow. Then 6 mL of
water were added to produce compound 2 as a white ﬂoating solid.
Compound 2 was washed with water, recovered by centrifugation,
and dried under vacuum. The dry product 2 was then dissolved in
1 mL of acetone, and an excess (270 mg) of NaI previously dried for
2 h at 110 °C was added. The halogen exchange reaction proceeded
Fig. 9. Proposed mechanism of action of i9 and other Ca2+ sensitizers. i9 selectively binds to cNTnC, reacts with C84, and promotes the open state to induce positive inotropy. A Ca2+
sensitizer may also bind to cNTnC and stabilize the open state without making a covalent bond. Only cNTnC and the inhibitory and switch regions of cTnI are shown after the ﬁrst
schematic for clarity.
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overnight at 37 °C with color change to orange and production of
bubbles and precipitation (NaCl). 5 mL each of ethyl acetate and H2O
were added to the reaction in a separation funnel. The yellow organic
phase was washed twice with water and once with 5% Na2S2O3 which
turned the solution clear. The clear organic phase was collected and
dried with anhydrous Na2SO4 until no clumps were observed. The
ﬁnal solution was evaporated, the i9 product redissolved in deuterated
dimethyl formamide, aliquoted, and stored at −20 °C wrapped in
aluminum foil. The purity and identity of the products was veriﬁed by
MS and NMR.
2.3. Troponin labeling with i9
Full cTnC(C35S), cNTnC (residues 1–89), and 13C,15N-cChimerawere
labeled under denaturing conditions. In addition, cNTnC was labeled in
aqueous buffer to assess the speciﬁcity of the reaction. The denaturing
buffer contained 6 M urea, 150 mM KCl, 50 mM TRIS, and 1 mM EGTA.
The aqueous buffer consisted of 100 mM KCl and 10 mM imidazole at
pH 8. The corresponding protein was dissolved in denaturing or aque-
ous buffer, 2 mM of fresh TCEP was added, and the solution incubated
for 30 min to reduce cysteine residues. A stock solution of i9 in DMF-
d7 was added in aliquots to the protein solution under stirring and the
pH was readjusted to 8. The protein solution remained clear before
the i9: protein ratio reached 1:1, afterwhich the solution became turbid.
The ﬁnal ratio was N2:1 for the reactions in urea and 1.2:1 for aqueous
buffer. The reaction proceeded in the dark with constant stirring at
27 °C for 16 h. The reaction was stopped with four times excess DTT
and spun down. The supernatant of the reaction in urea was applied
to a size exclusion chromatography column to purify the labeled protein
cTnC(C35S)-i9, cNTnC-i9, or cChimera-i9. The protein fraction was
lyophilized and stored at 4 °C.
2.4. Animals
Male Wistar rats (200–250 g) were stunned and killed by cervical
dislocation (Schedule 1 procedure in accordance with UK Animal
(Scientiﬁc Procedures) Act, 1986). The hearts were quickly removed
and rinsed free of blood in Krebs solution (Sigma-Aldrich, K4002) con-
taining: 118 mM NaCl, 24.8 mM NaHCO3, 1.18 mM Na2HPO4, 1.18 mM
MgSO4, 4.75 mM KCl, 2.54 mM CaCl2, 10 mM glucose, bubbled with
95% O2–5% CO2 for 30–60 min; pH 7.4 at 20 °C. Unbranched trabeculae
(diameter b250 μm) were dissected from the right ventricle in Krebs
solution containing 25mm2,3-butanedione-monoxime. The trabeculae
were permeabilized in relaxing solution (see below) containing 1%
Triton X-100 for 30 min, stored in relaxing solution containing
50% (v/v) glycerol at−20 °C for experiments, and used within 2 days
of dissection.
2.5. Reconstitution of cTnC(C35S)-i9 into ventricular trabeculae
Demembranated ventricular trabeculae were mounted via alumi-
num T-clips between a force transducer (AE801) and a ﬁxed hook in a
60 μl trough containing relaxing solution. The sarcomere length (SL)
was set to 2.1 μm by diffraction pattern using a Helium-Neon laser
(632.8 nm). Experimental solutions contained 25 mM imidazole,
5 mM MgATP, 1 mM free Mg2+, 10 mM EGTA (except pre-activating
solution), 0–10 mM total calcium, 1 mM dithiothreitol and 0.1% (v/v)
protease inhibitor cocktail (P8340, Sigma). Ionic strength was adjusted
to 200mMwith potassiumpropionate; pHwas 7.1 at 20 °C. The concen-
tration of free Ca2+ was calculated using the program WinMAXC V2.5
(http://web.stanford.edu/~cpatton/maxc.html). The calculated free
Ca2+ concentration was in the range 1 nM (pCa 9) to 41 μM (pCa
4.39). In pre-activating solution, the concentration of EGTA was
0.2mMandnocalciumwas added. For all experiments, the temperature
was 20–22 °C.
Trabecular activation was preceded by a 1 min incubation in pre-
activating solution. Isometric force was measured after steady-state
force had been established at each Ca2+ concentration. Maximum force
was recorded before and after each series of activations at submaximal
Ca2+ concentration. If the maximum force decreased by N15%, the
trabecula was discarded. The dependence of force on [Ca2+] was
ﬁtted to data from individual trabeculae using non-linear least-squares
regression to the Hill equation
Y ¼ 1
1þ 10nH pCapCa50ð Þ
  ð1Þ
where pCa50 is the pCa corresponding to half-maximal change and
nH is the Hill coefﬁcient. All values are given as mean ± standard error
of the mean except where noted, with n representing the number of
trabeculae.
Following initial characterization of Ca2+-dependent cardiac muscle
contraction containing native cTnC, cTnC was partially replaced by incu-
bating themounted trabeculae in relaxing solution containing 30 μmol/L
cTnC(C35S)-i9 for 15 min at 20–22 °C. The muscle was subsequently
washed 2–3 times in relaxing solution (without cTnC(C35S)-i9) and
the Ca2+-dependent cardiac muscle contraction was measured. If the
SL had changed during the exchange, it was re-set to 2.1 μm.
The fraction of TnC replaced by cTnC(C35S) was estimated to be
approximately 20% using LC-MS. Brieﬂy, following the cTnC(C35S)-i9
exchange, the trabeculae were incubated for 1 h in 50 mM BDM,
25 mM Tris (pH 8.4) and 5 mM CDTA to extract all cTnC (native and
cTnC(C35S)-i9). Due to the low concentration of cTnC, the extraction
solution from three muscle ﬁbers were combined and concentrated in
a 3 K Amicon Ultra Tube. The solution was loaded on a Hewlett Packard
(Agilent) 1100 Series LC/MSD using the electrospray ionizationmethod
and detected in positive mode. The spectrum was deconvoluted using
the Agilent ChemStation software with an abundance cutoff set to 40%.
2.6. NMR spectroscopy
The NMR samples consisted of 0.3–0.8mM cTnC(C35S)-i9, cNTnC-i9,
cChimera-i9, or cNTnC(C35S)-i9 in 500 or 600 μL of 100mMKCl, 10mM
imidazole or imidazole-d4, 2 mM CaCl2, and 0.25 mM 2,2-dimethyl-2-
silapentane-5-sulfonate-d6 sodium salt (DSS-d6) or triﬂuoroacetic acid
(TFA) as internal reference, at pH 6.9 (NMR buffer). The NMR experi-
ments were acquired in 500, 600, or 800 MHz Varian spectrometers at
30 °C. All one-dimensional experiments were processed with VnmrJ v
3.2, all the multidimensional spectra were processed with NMRPipe
[54] and analyzed with NMRViewJ [55]. The assignment of free i9
in DMSO was done based on examination of the 1H NMR spectra
Table 2
Summary of drug binding to cTnC.
Drug molecule Effect on Ca2+ sensitization Conformation of cNTnC KD (μM) cTnC/cTnC·cTnI Localization of switch-cTnI Afﬁnity of switch-cTnI
Bepridil Sensitizer Open 23/80 Shifted away from cNTnC ~3.5-fold decrease
Dfbp-o Sensitizer Open 820/380 Same as cNTnC·cTnI ~2.2-fold increase
Levosimendan Sensitizer – −/~200 – –
i9 Sensitizer Open Covalent Shifted away from cNTnC ~3-fold decrease
W7 Desensitizer Open ~230/500 Shifted away from cNTnC ~13-fold decrease
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acquired throughout the synthesis, and on previous assignment of the
levosimendan analog dfbp-o [25]. The assignment of i9 in cChimera-i9
was achieved using the 13C, 15N ﬁltered noesy, 13C, 15N ﬁltered tocsy,
and 1H, 19F HMQC spectra (Supporting Figure 3 and Supporting
Table 2). Assignment of cChimera in cChimera-i9was done by using typ-
ical 2d and 3d NMR experiments 1H, 15N- and 1H, 13C-HSQC, HNCACB,
CBCA(CO)NH, HNHA, HCCONH, and CCONH detailed in Supporting
Table 2.
2.7. Switch-cTnI titration into cTnC(C35S)-i9
A solution of 530 μM cTnC(C35S)-i9 in NMR buffer was titrated with
increasing amounts of switch-cTnI (residues 144–163) using a stock
solution of 10.6 mM in DMSO-d6. The concentration of the protein solu-
tion was determined by amino acid analysis. The concentration of the
stock solution was determined by NMR spectral integration of the
methyl signals relative to that of a DSS-d6 standard. The concentration
of switch-cTnI at each titration point was 0, 86, 169, 251,334, 415,
575, 810, 1,115, and 1,540 μM. The diluting effect of each switch-cTnI
additionwas taken in considerationwhen calculating the concentration
of protein and peptide at each titration point. 1H and 19F NMR spectra
were acquired after each addition of switch-cTnI. The change of area
under the F4′ signal of i9 as a function of the switch-cTnI/cTnC(C35S)
ratio was ﬁt using a one-to-one stoichiometry with xcrvﬁt (www.
bionmr.ualberta.ca/wiki/index.php/Main_Page).
2.8. Structure determination
The structure of i9 bound to cChimera was determined using Xplor-
NIH v. 2.35 with experimental backbone dihedral and distance
restraints. Parameter and topology ﬁles for i9 covalently attached to
cysteine were generated using the PRODRG server [56] (http://
davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg/). The dihedral angles φ
and ψ were predicted with the Talos+ server (http://spin.niddk.nih.
gov/bax/nmrserver/talos/) based on the chemical shift of HN, N, CA,
CB, and HA backbone atoms of cChimera-i9. Intramolecular distance re-
straints within the protein component of cChimera-i9 were obtained
from noesyNhsqc and noesyChsqc NMR spectra, NOEs were calibrated
using the bin method of NMRViewJ and classiﬁed as strong (1.8–3 Å),
medium (3–4.5 Å), and weak (4.5–6 Å). Intramolecular NOEs within
i9 were obtained from the 13C, 15N ﬁltered noesy spectrum in which
signals from the 13C, 15N labeledproteinmoiety are ﬁltered out to obtain
NOEs from the unlabeled drug moiety only. Pseudo-intermolecular
NOEs between cChimera and i9 were obtained from the three-
dimensional noesyChsqc_CNﬁlt NMR spectrum; all of these were
classiﬁed as weak (1.8–6 Å). We used statistical torsion angle potential
to improve the quality of backbone and side chain conformations; this is
based on over a million residues from high quality crystal structures
from the PDB. We also used the gyration volume potential term to re-
strain the volume associated with the gyration tensor also based on
values observed in the PDB. We used the anneal protocol of Xplor-NIH
to generate 140 structures from which the lowest energy structure
was used in the subsequent reﬁne protocol. The ﬁnal ensemble consists
of the 20 lowest energy structures generated in the reﬁnement step
with no NOE violations N0.4 Å or dihedral violation N5°. This ensemble
was validated with PROCHECK using the Protein Structure Validation
Suite (PSVS 1.5) server (http://psvs-1_5-dev.nesg.org/).
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